Uncategorized

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

Posted on

Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease Takeda acquires exclusive global license to investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease Osaka, […]

Uncategorized

Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA

Posted on

Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA – A Novel Treatment for Celiac Disease under Clinical Development TIMP-GLIA is designed to enable patients to develop tolerance to gluten Phase 1 program studying potential of new treatment option for people living with Celiac Disease   CHICAGO, Wednesday, January 10, 2018 Cour Pharmaceuticals today announced that […]

Uncategorized

Cour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA – A Novel Treatment for Celiac Disease

Posted on

CHICAGO, August 21, 2017   Cour Pharmaceuticals, a specialty pharma company focused on autoimmune, allergic, and inflammatory diseases, announces that its Investigational New Drug (IND) for TIMP-GLIA is now open with the US Food & Drug Administration (FDA).   TIMP-GLIA is a new nanoparticle-based therapeutic for the treatment of celiac disease. By encapsulating a component […]

Uncategorized

Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease

Posted on

 Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases  Osaka, Japan, December 8, 2015, and Chicago, Ill., December 7, 2015 – Takeda Pharmaceutical Company Limited (TSE: 4502) and Cour Pharmaceutical Development Company, Inc. today announced a partnership to research and develop novel immune modulating therapies for the potential treatment […]

Uncategorized

Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease

Posted on

Proprietary antigen-specific nanoparticles and cure for celiac disease Chicago (June 22, 2015) – Cour Pharmaceutical Development Company today announced new data from a preclinical live animal study demonstrating a breakthrough approach for celiac disease treatment. The data shows a reversal of the effects of dietary gluten exposure, and is being presented during the 16th Annual […]